Limula has confirmed the granting of a core patent in the United States, further strengthening its position in the field of automated cell and gene therapy (CGT) manufacturing. The US patent is the latest addition to the company’s international intellectual property portfolio, which already includes protection in several key global markets.

The newly granted patent covers the company’s proprietary technology — a closed, programmable, and modular system designed to consolidate the various unit operations involved in cell therapy production. This includes cell incubation, washing, separation, and other key steps that would typically require multiple tools or manual handling.

Luc Henry, CEO and co-founder of Limula, said: “The IP protection strengthens Limula’s competitive position as we anticipate product launch and continue to engage with hospitals, biotechs, CDMOs, and pharmaceutical partners worldwide in our early access program. This patent is a key milestone in our broader strategy to protect the core innovations behind our platform. We will continue to build our IP portfolio as we progress towards making these personalized treatments scalable and accessible to more patients.”

The company’s platform is designed to enable the production of autologous cell therapies — treatments made from a patient’s own cells — within a single device. By integrating multiple steps into one closed system, the technology reduces the need to transfer cells between separate machines. This approach eliminates common sources of variability, lowers consumable use, and minimizes manual intervention. According to Limula, the system may support more decentralized and scalable approaches to manufacturing, including point-of-care settings such as hospital labs.

The patent also protects what the company describes as a novel way to program and orchestrate the manufacturing steps within the same device, which could have implications for digital control and reproducibility across multiple clinical and commercial sites. This aspect of the technology may be particularly relevant as developers seek to reduce batch failures and improve process standardization.

Limula is currently inviting partners to join its early access program, which aims to evaluate the performance of the system in real-world manufacturing and clinical settings. The company is actively collaborating with stakeholders across the CGT ecosystem, including contract manufacturers, academic groups, and hospitals, as part of its development and commercialization strategy.